Combined Company to Benefit from Anticipated Significant Expense Savings, Improved Scale and Capital Efficiency Represents Over $110 Million in Combined […]
BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) — HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing […]